Centessa Pharmaceuticals (CNTA) Net Income towards Common Stockholders (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Net Income towards Common Stockholders of -$79.2 million for Q1 2026, down 203.2% year-over-year from $76.8 million in Q1 2025, and down 19.77% quarter-over-quarter from -$66.2 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$79.2 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$79.2 million, down 203.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$250.6 million (down 11.97% YoY), and the FY2025 annual result was -$197.5 million, up 16.21% from the prior year.
- Net Income towards Common Stockholders eased to -$79.2 million in Q1 2026 per CNTA's latest filing, from -$66.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$24.9 million in Q2 2023 and troughed at -$111.3 million in Q4 2024.
- A 5-year average of -$51.8 million and a median of -$50.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders soared 77.17% in 2022, then slumped 203.2% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$43.2 million in 2022, then gained by 14.68% to -$36.8 million in 2023, then tumbled by 202.22% to -$111.3 million in 2024, then surged by 40.57% to -$66.2 million in 2025, then retreated by 19.77% to -$79.2 million in 2026.
- Business Quant data shows CNTA's Net Income towards Common Stockholders at -$79.2 million in Q1 2026, -$66.2 million in Q4 2025, and -$54.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Centessa Pharmaceuticals | 6.10 Bn | 6.10 Bn | - | -79.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.24 Mn |
| Dec 31, 2025 | -66.16 Mn |
| Sep 30, 2025 | -54.89 Mn |
| Jun 30, 2025 | -50.34 Mn |
| Mar 31, 2025 | -26.14 Mn |
| Dec 31, 2024 | -111.33 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -43.82 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Dec 31, 2023 | -36.84 Mn |
| Sep 30, 2023 | -38.65 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -50.71 Mn |
| Dec 31, 2022 | -43.17 Mn |
| Sep 30, 2022 | -53.92 Mn |
| Jun 30, 2022 | -64.66 Mn |
| Mar 31, 2022 | -54.50 Mn |
| Dec 31, 2021 | -60.77 Mn |
| Sep 30, 2021 | -40.16 Mn |
| Jun 30, 2021 | -41.45 Mn |